Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development and characterization of dried blood spot materials for the measurement of immunoreactive trypsinogen.

Journal of medical screening - 1 Jan 2006

Li Lixia, Zhou Yingtao, Bell Carol J, Earley Marie C, Hannon W Harry, Mei Joanne V

Abstract excerpt

OBJECTIVES: In response to increasing numbers of states in the US that test newborn babies for cystic fibrosis (CF), the Newborn Screening Quality Assurance Programme initiated a pilot proficiency testing programme for immunoreactive trypsinogen (IRT), the biomarker for CF. Dried blood spot specimens (DBS) were used to evaluate the performance of laboratories that screen babies for CF. METHODS: DBS were prepared...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cystic Fibrosis
Share to Mass Screening

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neonatal Screening

Share to Pilot Projects

Share to Protease Inhibitors

Share to Quality Control

Share to Specimen Handling

Share to Trypsinogen

Source

Identifiers

PMID: 16792830
DOI: 10.1258/096914106777589623

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development and characterization of dried blood spot materials for the measurement of immunoreactive trypsinogen.PMID 16792830Read ↗

Improving the Sensitivity and Positive Predictive Value in a Cystic Fibrosis Newborn Screening Program Using a Repeat Immunoreactive Trypsinogen and Genetic Analysis.Semantic proximity Read ↗

Screening for cystic fibrosis in New York State: considerations for algorithm improvements.Semantic proximity Read ↗

Susceptibility haplotypes in non-cystic fibrosis newborns with elevated immunoreactive trypsinogenSemantic proximity Read ↗

Immunoreactive Trypsinogen in Infants Born to Women with Cystic Fibrosis Taking Elexacaftor–Tezacaftor–IvacaftorSemantic proximity Read ↗

Newborn screening for cystic fibrosis in Serbia: a pilot study.Semantic proximity Read ↗

Storing Newborn Blood Spots: Modern ControversiesSemantic proximity Read ↗

Pilot study for cystic fibrosis neonatal screening: the Cuban experience.Semantic proximity Read ↗

Cystic fibrosis carriers have higher neonatal immunoreactive trypsinogen values than non-carriers.Semantic proximity Read ↗

A new cystic fibrosis newborn screening algorithm: IRT/IRT1 upward arrow/DNA.Semantic proximity Read ↗

Development of mutant human immunoreactive trypsinogen 1 (IRT1) and mutant human immunoreactive trypsinogen 2 (IRT2) for use in immunoassays.Semantic proximity Read ↗

Combining Immunoreactive Trypsinogen and Pancreatitis-Associated Protein Assays, a Method of Newborn Screening for Cystic Fibrosis that Avoids DNA AnalysisSemantic proximity Read ↗

Neonatal screening for cystic fibrosis using immunoreactive trypsinogen and direct gene analysis: four years' experience.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.